These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 19077695)

  • 1. Mechanisms of kidney fibrosis and the role of antifibrotic therapies.
    Deelman L; Sharma K
    Curr Opin Nephrol Hypertens; 2009 Jan; 18(1):85-90. PubMed ID: 19077695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of a local renin angiotensin system in podocytes by glucose.
    Durvasula RV; Shankland SJ
    Am J Physiol Renal Physiol; 2008 Apr; 294(4):F830-9. PubMed ID: 18216149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review: Endothelial-myofibroblast transition, a new player in diabetic renal fibrosis.
    Li J; Bertram JF
    Nephrology (Carlton); 2010 Aug; 15(5):507-12. PubMed ID: 20649869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of TGF-β in chronic kidney disease: an integration of tubular, glomerular and vascular effects.
    López-Hernández FJ; López-Novoa JM
    Cell Tissue Res; 2012 Jan; 347(1):141-54. PubMed ID: 22105921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Abnormality of renin-angiotensin system in podocyte dysfunction in diabetic kidney disease].
    Shao DC; Lu LM
    Sheng Li Ke Xue Jin Zhan; 2011 Aug; 42(4):246-50. PubMed ID: 22066414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Podocyte hypertrophy in diabetic nephropathy.
    Kim NH
    Nephrology (Carlton); 2005 Oct; 10 Suppl():S14-6. PubMed ID: 16174280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Research into the glomerular podocyte--is it relevant to diabetic nephropathy?
    White KE
    Diabet Med; 2006 Jul; 23(7):715-9. PubMed ID: 16842474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression of chronic kidney disease: can it be prevented or arrested?
    Jaber BL; Madias NE
    Am J Med; 2005 Dec; 118(12):1323-30. PubMed ID: 16378772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relaxin and the progression of kidney disease.
    Samuel CS; Hewitson TD
    Curr Opin Nephrol Hypertens; 2009 Jan; 18(1):9-14. PubMed ID: 19077683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesenchymal stem cell therapy promotes renal repair by limiting glomerular podocyte and progenitor cell dysfunction in adriamycin-induced nephropathy.
    Zoja C; Garcia PB; Rota C; Conti S; Gagliardini E; Corna D; Zanchi C; Bigini P; Benigni A; Remuzzi G; Morigi M
    Am J Physiol Renal Physiol; 2012 Nov; 303(9):F1370-81. PubMed ID: 22952284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The podocyte and diabetes mellitus: is the podocyte the key to the origins of diabetic nephropathy?
    Reddy GR; Kotlyarevska K; Ransom RF; Menon RK
    Curr Opin Nephrol Hypertens; 2008 Jan; 17(1):32-6. PubMed ID: 18090667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Innovative antifibrotic therapies in systemic sclerosis.
    Beyer C; Distler O; Distler JH
    Curr Opin Rheumatol; 2012 May; 24(3):274-80. PubMed ID: 22450392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Mechanisms in remodeling of the kidney].
    Nangaku M; Miyata T
    Nihon Rinsho; 2008 Sep; 66(9):1696-700. PubMed ID: 18788396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic targets for treating fibrotic kidney diseases.
    Lee SY; Kim SI; Choi ME
    Transl Res; 2015 Apr; 165(4):512-30. PubMed ID: 25176603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic kidney disease growth factors in renal fibrosis.
    Boor P; Floege J
    Clin Exp Pharmacol Physiol; 2011 Jul; 38(7):441-50. PubMed ID: 21276040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Reversal of renal fibrosis: lessons from experimental models].
    Dussaule JC; Chatziantoniou C
    Bull Acad Natl Med; 2008 May; 192(5):987-1000; discussion 1000-1. PubMed ID: 19238788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokines and renin-angiotensin system signaling in hepatic fibrosis.
    Moreno M; Bataller R
    Clin Liver Dis; 2008 Nov; 12(4):825-52, ix. PubMed ID: 18984469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Podocytes, glucose and insulin.
    Welsh GI; Coward RJ
    Curr Opin Nephrol Hypertens; 2010 Jul; 19(4):379-84. PubMed ID: 20539231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting podocyte-associated diseases.
    Leeuwis JW; Nguyen TQ; Dendooven A; Kok RJ; Goldschmeding R
    Adv Drug Deliv Rev; 2010 Nov; 62(14):1325-36. PubMed ID: 20828590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epithelial-mesenchymal crosstalk alteration in kidney fibrosis.
    Prunotto M; Budd DC; Gabbiani G; Meier M; Formentini I; Hartmann G; Pomposiello S; Moll S
    J Pathol; 2012 Oct; 228(2):131-47. PubMed ID: 22570261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.